Read the poster preso title it tells you everything you need to know - they are going to be talking about the enhancement of pharmacokinetics of the drug due to adding IL2.
Here is the title...
Absract title: Administration of Low-Dose, Subcutaneous (SC) Interleukin-2 (IL-2) Markedly Enhances the Pharmacokinetic (PK) Profile of Azercabtagene Zapreleucel (azer-cel), an Allogeneic Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, without Compromising Safety and Early Evidence of Clinical Activity in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Have Relapsed after Prior CD19-Directed
CAR T-Cell Products.
Doesn't mean it's bad - it's just early stages - so don't get too excited - there will not be any new efficacy data etc.
How do I know? Cause the title tells you what they are presenting.
(20min delay)